Lupus Nephritis Clinical Trials, Lupus Nephritis: Diagnosis and Management, Glomerulonephritis: Caus скачать в хорошем качестве

Lupus Nephritis Clinical Trials, Lupus Nephritis: Diagnosis and Management, Glomerulonephritis: Caus

A 25-year-old woman with systemic lupus erythematosus presents with acute dyspnea, hypotension, oliguria, and nephrotic-range proteinuria in the ICU. Examination reveals edema, crackles, and classic lupus findings, while labs show active kidney involvement and low complement. What elements of her presentation and recent trial data should guide your nephrology management, and which clinical factors are critical for optimizing treatment as she stabilizes? VIDEO INFO Category: Lupus Nephritis Clinical Trials, Lupus Nephritis: Diagnosis and Management, Glomerulonephritis: Causes, Diagnosis, and Management, Nephrology: Kidney Disease Diagnosis and Management Difficulty: Expert - Expert level - For those seeking deep understanding Question Type: Recent Changes Case Type: Critical Condition Explore more ways to learn on this and other topics by going to https://endlessmedical.academy/auth?h... QUESTION A 25-year-old woman with SLE (no known allergies) is brought to the ICU with 24 hours of dyspnea and oliguria. Vitals: pulse 85, respirations 8, blood pressure 44/27 mm Hg (dopamine started), temperature 37.0 degreesC, SpO2 99% on high-flow. Past history includes atrial fibrillation (no anticoagulant currently), repaired Boerhaave syndrome 2 years ago, asthma, and panic disorder.... OPTIONS A. Initiate pulse methylprednisolone then mycophenolate mofetil 1 g twice daily with add-on belimumab IV 10 mg/kg at weeks 0, 2, and 4 then every 4 weeks, plus ACEi and hydroxychloroquine, with steroid minimization per 2024 ACR/KDIGO triple-therapy guidance in ICU. B. Start cyclophosphamide 750 mg/m2 IV monthly for six months with high-dose oral prednisone =1 mg/kg/day for 3-6 months, then taper after discharge once proteinuria is below 1 g/day and complements normalize. C. Begin voclosporin 23.7 mg twice daily with mycophenolate 2 g/day and maintain prednisone 20-25 mg/day without rapid taper until week 24, deferring any biologic therapy and postponing ACE inhibitor introduction. D. Administer obinutuzumab 1000 mg on day 1 and week 2 with background azathioprine 2 mg/kg/day and maintain prednisone 0.5 mg/kg/day for 12 months, avoiding mycophenolate because of infection risk during respiratory failure; reassess proteinuria only after week 52. CORRECT ANSWER A. Initiate pulse methylprednisolone then mycophenolate mofetil 1 g twice daily with add-on belimumab IV 10 mg/kg at weeks 0, 2, and 4 then every 4 weeks, plus ACEi and hydroxychloroquine, with steroid minimization per 2024 ACR/KDIGO triple-therapy guidance in ICU. EXPLANATION Following hemodynamic stabilization and infection control, early steroid minimization with add-on therapy layered on MMF for new class IV-G LN aligns with KDIGO 2024 and ACR 2024 updates. The correct regimen initiates pulse methylprednisolone, then MMF 1 g twice daily with belimumab 10 mg/kg at weeks 0, 2, and 4 then every 4 weeks, while integrating ACE inhibitor and hydroxychloroquine as tolerated. This mirrors triple-therapy paradigms that improved composite renal responses and enable faster glucocorticoid tapering from the ICU to the ward. The alternatives diverge from contemporary evidence. High-dose cyclophosphamide with prolonged =1 mg/kg/day prednisone for months conflicts with steroid-minimization targets and exposes to excess toxicity. Voclosporin plus MMF can be appropriate when eGFR =45 and BP/K+ permit, but sustaining prednisone 20-25 mg/day without early taper and postponing ACE inhibition contradicts trial steroid protocols and guideline BP/proteinuria management.... Further reading: Links to sources are provided for optional further reading only. The questions and explanations are independently authored and do not reproduce or adapt any specific third-party text or content. --------------------------------------------------- Our cases and questions come from the https://EndlessMedical.Academy quiz engine - multi-model platform. Each question and explanation is forged by consensus between multiple top AI models (i.e. Open AI GPT, Claude, Grok, etc.), with automated web searches for the latest research and verified references. Calculations (e.g. eGFR, dosages) are checked via code execution to eliminate errors, and all references are reviewed by several AIs to minimize hallucinations. Important note: This material is entirely AI-generated and has not been verified by human experts; despite stringent consensus checks, perfect accuracy cannot be guaranteed. Exercise caution - always corroborate the content with trusted references or qualified professionals, and never apply information from this content to patient care or clinical decisions without independent verification. Clinicians already rely on AI and online tools - myself included - so treat this content as an additional focused aid, not a replacement for proper medical education. Visit https://endlessmedical.academy for more AI-supported resources and cases. This material can not be treated as medical adv